Ofev May Be Less Tolerable Over Long Term in IPF Patients in Poorer Health

Ofev May Be Less Tolerable Over Long Term in IPF Patients in Poorer Health

284869

Ofev May Be Less Tolerable Over Long Term in IPF Patients in Poorer Health

People with idiopathic pulmonary fibrosis (IPF) in poorer health are less likely than healthier patients to tolerate more than one year of treatment with Ofev (nintedanib), and benefit less from the therapy than those able to continue with its use, a small real-world study reports. Side effects that included nausea, and disease progression were the main reasons IPF patients being followed at two hospitals in Japan stopped the treatment after 12 months, its researchers noted.…

You must be logged in to read/download the full post.